Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

Detalles Bibliográficos
Autores principales: Tiacci, Enrico, De Carolis, Luca, Simonetti, Edoardo, Merluzzi, Mara, Bennati, Antonio, Perriello, Vincenzo Maria, Pucciarini, Alessandra, Santi, Alessia, Venanzi, Alessandra, Pettirossi, Valentina, Schiavoni, Gianluca, Tasselli, Luisa, Ascani, Stefano, Volpetti, Stefano, Falini, Brunangelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550943/
https://www.ncbi.nlm.nih.gov/pubmed/33731847
http://dx.doi.org/10.1038/s41375-021-01210-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550943/
https://www.ncbi.nlm.nih.gov/pubmed/33731847
http://dx.doi.org/10.1038/s41375-021-01210-8

Ejemplares similares